Company Profile
ImmunityBio Stock Price, News & Analysis
- Ticker:
- IBRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.32 USD (+0.97%)
Close
Last updated: August 6, 2026
7.57B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, IBRX closed up 0.97% at $7.32. No new same-company headline was identified in the current news window.
Company overview
Immune-Based Cancer Therapies
ImmunityBio develops therapies that activate innate and adaptive immune responses against cancer. Its platform combines cytokine biology, cell therapy and immunotherapy combinations.
ANKTIVA
ANKTIVA is an IL-15 superagonist approved with BCG for selected patients with BCG-unresponsive non-muscle-invasive bladder cancer. It is the company's principal commercial product.
BCG-Naive Bladder Cancer
The fully enrolled QUILT-2.005 pivotal study evaluates ANKTIVA with BCG in BCG-naive carcinoma in situ and is intended to support a supplemental BLA.
Lung-Cancer Development
ImmunityBio is also advancing ANKTIVA-based immunotherapy combinations in non-small cell lung cancer, extending the platform into systemic solid-tumor treatment.
Future catalysts
Supplemental BLA submission for ANKTIVA in BCG-naive carcinoma in situ during 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ImmunityBio (IBRX)?
ImmunityBio (IBRX) most recently closed at 7.32 USD, a +0.97% move versus the previous session.
What is the market cap of ImmunityBio (IBRX)?
ImmunityBio currently has a market capitalization of 7.57B USD on BioPharmSignal.
What does ImmunityBio do?
Immune-Based Cancer Therapies ImmunityBio develops therapies that activate innate and adaptive immune responses against cancer. Its platform combines cytokine biology, cell therapy and immunotherapy combinations. ANKTIVA ANKTIVA is an IL-15 superagonist approved with BCG for selected patients with BCG-unresponsive non-muscle-invasive bladder cancer. It is...
On which exchange is IBRX stock listed?
ImmunityBio (IBRX) is associated with NASDAQ, United States, Biopharma.
What is IL-15?
ANKTIVA ANKTIVA is an IL-15 superagonist approved with BCG for selected patients with BCG-unresponsive non-muscle-invasive bladder cancer.
Which conditions is ImmunityBio targeting with IL-15?
ImmunityBio is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does ImmunityBio describe recent progress with IL-15?
Supplemental BLA submission for ANKTIVA in BCG-naive carcinoma in situ during 2026.
What is QUILT-2?
BCG-Naive Bladder Cancer The fully enrolled QUILT-2.005 pivotal study evaluates ANKTIVA with BCG in BCG-naive carcinoma in situ and is intended to support a supplemental BLA.